Please assess the completion status of the following clinical trial:

Trial Title: A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Female patients, ≥ 18 years of age.~* Epithelial ovarian, fallopian tube, or primary peritoneal cancer.~* Initial surgery, but no chemotherapy or radiotherapy.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.~Exclusion Criteria~* Non-epithelial tumors.~* Ovarian tumors with low malignant potential.~* Previous systemic anti-cancer therapy for ovarian cancer.~* History or evidence of synchronous primary endometrial cancer.~* Current or recent daily treatment with aspirin (\> 325mg/day) or with full dose anticoagulant or thrombolytic agents for therapeutic purposes.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + paclitaxel + carboplatin (Type: EXPERIMENTAL): Participants received 6-8 (at the investigator's discretion) 3-week cycles of bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m\^2 iv on Days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve of 6 on Day 1 of each cycle. The initial dose of carboplatin was calculated according to the Calvert formula (mg = \[glomerular filtration rate + 25\] x 6). Following the combination treatments, participants received up to 17 3-week cycles of bevacizumab 7.5 mg/g iv alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).